We are now entering a new era of RNA therapies, such that mRNA-based vaccines and RNA interference approaches such as siRNA have already been launched on the pharmaceutical market. However, there are no FDAapproved RNA-based therapeutics for cancer treatment. Among RNA molecules, miRNAs represent a promisingsolution against cancer. Despite the ability to target multiple pathways, miRNA-based therapeutics struggle toreach phase 3 clinical trial. A reason of this delay is linked to complications of selective administration of miRNAsto their target, the tumor cell. Because of this, an efficient delivery system is necessary. In this sense, exosomes areconsidered the most promising miRNA-based therapeutic carriers in terms of safety and efficient cargo delivery.Furthermore, researchers have developed a new strategy to overcome the tumor capacity by using exosomes torelease unnecessary miRNAs, shedding light on a new generation therapy of cancer treatment. The review describes recent advances in the application of miRNAs in the treatment of cancer, the use of exosomes for miRNAdelivery, focusing on new approaches to overcome the limits of miRNA-loaded exosomes in clinical applications.
Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery / Volpini, Luca; Monaco, Federica; Santarelli, Lory; Neuzil, Jiri; Tomasetti, Marco. - In: ASPECTS OF MOLECULAR MEDICINE. - ISSN 2949-6888. - 1:(2023). [10.1016/j.amolm.2023.100005]
Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery
Luca Volpini;Federica MonacoSecondo
;Lory Santarelli;Marco Tomasetti
2023-01-01
Abstract
We are now entering a new era of RNA therapies, such that mRNA-based vaccines and RNA interference approaches such as siRNA have already been launched on the pharmaceutical market. However, there are no FDAapproved RNA-based therapeutics for cancer treatment. Among RNA molecules, miRNAs represent a promisingsolution against cancer. Despite the ability to target multiple pathways, miRNA-based therapeutics struggle toreach phase 3 clinical trial. A reason of this delay is linked to complications of selective administration of miRNAsto their target, the tumor cell. Because of this, an efficient delivery system is necessary. In this sense, exosomes areconsidered the most promising miRNA-based therapeutic carriers in terms of safety and efficient cargo delivery.Furthermore, researchers have developed a new strategy to overcome the tumor capacity by using exosomes torelease unnecessary miRNAs, shedding light on a new generation therapy of cancer treatment. The review describes recent advances in the application of miRNAs in the treatment of cancer, the use of exosomes for miRNAdelivery, focusing on new approaches to overcome the limits of miRNA-loaded exosomes in clinical applications.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2949688823000059-main.pdf
accesso aperto
Descrizione: Full-text
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Creative commons
Dimensione
1.29 MB
Formato
Adobe PDF
|
1.29 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


